Jose L. Lopez-Ribot to Antifungal Agents
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Antifungal Agents.
Connection Strength
13.568
-
Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS. 2023 Nov; 131(11):613-625.
Score: 0.717
-
Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? APMIS. 2023 Nov; 131(11):636-653.
Score: 0.706
-
Lara HH, Ixtepan-Turrent L, Jose Yacaman M, Lopez-Ribot J. Inhibition of Candida auris Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles. ACS Appl Mater Interfaces. 2020 May 13; 12(19):21183-21191.
Score: 0.565
-
Vazquez-Mu?oz R, Arellano-Jimenez MJ, Lopez FD, Lopez-Ribot JL. Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities. BMC Res Notes. 2019 Nov 27; 12(1):773.
Score: 0.560
-
Romo JA, Zhang H, Cai H, Kadosh D, Koehler JR, Saville SP, Wang Y, Lopez-Ribot JL. Global Transcriptomic Analysis of the Candida albicans Response to Treatment with a Novel Inhibitor of Filamentation. mSphere. 2019 09 11; 4(5).
Score: 0.552
-
Wall G, Chaturvedi AK, Wormley FL, Wiederhold NP, Patterson HP, Patterson TF, Lopez-Ribot JL. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrob Agents Chemother. 2018 10; 62(10).
Score: 0.516
-
Romo JA, Pierce CG, Esqueda M, Hung CY, Saville SP, Lopez-Ribot JL. In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Front Cell Infect Microbiol. 2018; 8:227.
Score: 0.509
-
Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP, Lopez-Ribot JL. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. mBio. 2017 Dec 05; 8(6).
Score: 0.488
-
Vila T, Lopez-Ribot JL. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother. 2017 01; 61(1).
Score: 0.457
-
Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 2017 02 17; 8(2):150-158.
Score: 0.440
-
Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence. 2017 02 17; 8(2):138-142.
Score: 0.440
-
Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
Score: 0.420
-
Pierce CG, Srinivasan A, Ramasubramanian AK, L?pez-Ribot JL. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr. 2015 Jun; 3(3).
Score: 0.410
-
Pierce CG, Saville SP, Lopez-Ribot JL. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis. 2014 Apr; 70(3):423-31.
Score: 0.377
-
Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2014; 58(2):1183-6.
Score: 0.368
-
Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, L?pez-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013 Oct; 13(5):726-30.
Score: 0.364
-
Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep; 8(9):1117-26.
Score: 0.357
-
Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
Score: 0.309
-
Pierce CG, Uppuluri P, Tummala S, Lopez-Ribot JL. A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp. 2010 Oct 21; (44).
Score: 0.298
-
Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009 Sep; 64(3):567-70.
Score: 0.272
-
Redding S, Bhatt B, Rawls HR, Siegel G, Scott K, Lopez-Ribot J. Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 May; 107(5):669-72.
Score: 0.269
-
Saeger S, West-Jeppson K, Liao Y-R, Campuzano A, Yu J-J, Lopez-Ribot J, Hung C-Y. Discovery of novel antifungal drugs via screening repurposing libraries against Coccidioides posadasii spherule initials. mBio. 2025 May 14; 16(5):e0020525.
Score: 0.203
-
Ramage G, Kean R, Rautemaa-Richardson R, Williams C, Lopez-Ribot JL. Fungal biofilms in human health and disease. Nat Rev Microbiol. 2025 Jun; 23(6):355-370.
Score: 0.201
-
Ramage G, L?pez-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med. 2005; 118:71-9.
Score: 0.199
-
Li X, Brown N, Chau AS, L?pez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan; 53(1):74-80.
Score: 0.185
-
Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, L?pez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003 Nov; 47(11):3657-9.
Score: 0.184
-
Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003 Feb; 41(2):619-22.
Score: 0.175
-
Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
Score: 0.173
-
Ramage G, VandeWalle K, Bachmann SP, Wickes BL, L?pez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002 Nov; 46(11):3634-6.
Score: 0.172
-
Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
Score: 0.167
-
Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
Score: 0.158
-
Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab. 2001 Aug; 20(7):42-4.
Score: 0.157
-
Wall G, Chen E, Hull MV, Lopez-Ribot JL. Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation. Front Cell Infect Microbiol. 2020; 10:597931.
Score: 0.150
-
Wall G, Lopez-Ribot JL. Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity. Antimicrob Agents Chemother. 2020 08 20; 64(9).
Score: 0.147
-
Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, La Valle R, Patterson TF. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Clin Diagn Lab Immunol. 1999 Sep; 6(5):665-70.
Score: 0.138
-
Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov; 42(11):2932-7.
Score: 0.130
-
Dekkerov? J, Lopez-Ribot JL, Bujd?kov? H. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen. Eur J Clin Microbiol Infect Dis. 2019 Jan; 38(1):101-108.
Score: 0.130
-
Lara HH, Guisbiers G, Mendoza J, Mimun LC, Vincent BA, Lopez-Ribot JL, Nash KL. Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against Candida albicans biofilms. Int J Nanomedicine. 2018; 13:2697-2708.
Score: 0.126
-
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discov Today Technol. 2014 Mar; 11:65-71.
Score: 0.094
-
Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol Bioeng. 2014 Feb; 111(2):418-24.
Score: 0.092
-
Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-throughput nano-biofilm microarray for antifungal drug discovery. mBio. 2013 Jun 25; 4(4).
Score: 0.090
-
Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother. 2013 Aug; 57(8):3681-7.
Score: 0.089
-
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp. 2012 Jul 18; (65):e3845.
Score: 0.084
-
Martins M, Lazzell AL, Lopez-Ribot JL, Henriques M, Oliveira R. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol. 2012 Aug; 52(4):487-91.
Score: 0.080
-
Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
Score: 0.078
-
Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol. 2009 Dec; 47(12):4078-83.
Score: 0.069
-
Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia. 2009 Sep; 168(3):101-9.
Score: 0.067
-
Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets. 2006 Dec; 6(4):335-41.
Score: 0.057
-
Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006 Oct; 50(10):3312-6.
Score: 0.056
-
Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
Score: 0.054
-
Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
Score: 0.047
-
Viudes A, Pem?n J, Cant?n E, Ubeda P, L?pez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002 Nov; 21(11):767-74.
Score: 0.043
-
Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
Score: 0.042
-
Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
Score: 0.042
-
Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.
Score: 0.041
-
Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
Score: 0.041
-
Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
Score: 0.040
-
Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Biofilm formation by Candida dubliniensis. J Clin Microbiol. 2001 Sep; 39(9):3234-40.
Score: 0.040
-
Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
Score: 0.032
-
Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011 Sep; 7(9):e1002257.
Score: 0.020
-
Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. PLoS One. 2011 Apr 22; 6(4):e19036.
Score: 0.019
-
S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005 Jun; 22(2):83-92.
Score: 0.013
-
Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
Score: 0.012
-
Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
Score: 0.011
-
Viudes A, Pem?n J, Cant?n E, Salavert M, Ubeda P, L?pez-Ribot JL, Gobernado M. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis. 2002 Apr; 21(4):294-9.
Score: 0.010
-
Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
Score: 0.010
-
Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 1999 Dec; 37(12):3896-900.
Score: 0.009